Abstract
BackgroundBreast cancer is the most diagnosed malignancy in females in the United States. The members of retinal determination gene network (RDGN) including DACH, EYA, as well as SIX families participate in the proliferation, apoptosis, and metastasis of multiple tumors including breast cancer. A comprehensive predictive model of RDGN might be helpful to herald the prognosis of breast cancer patients.MethodsIn this study, the Gene Expression Ominibus (GEO) and Gene Set Expression Analysis (GSEA) algorithm were used to investigate the effect of RDGN members on downstream signaling pathways. Besides, based on The Cancer Genome Atlas (TCGA) database, we explored the expression patterns of RDGN members in tumors, normal tissues, and different breast cancer subtypes. Moreover, we estimated the relationship between RDGN members and the outcomes of breast cancer patients. Lastly, we constructed a RDGN-based predictive model by Cox proportional hazard regression and verified the model in two separate GEO datasets.ResultsThe results of GSEA showed that the expression of DACH1 was negatively correlated with cell cycle and DNA replication pathways. On the contrary, the levels of EYA2 and SIX1 were significantly positively correlated with DNA replication, mTOR, and Wnt pathways. Further investigation in TCGA database indicated that DACH1 expression was lower in breast cancers especially basal-like subtype. In the meanwhile, SIX1 was remarkably upregulated in breast cancers while EYA2 level was increased in Basal-like and Her-2 enriched subtypes. Survival analyses demonstrated that DACH1 was a favorable factor while EYA2 and SIX1 were risk factors for breast cancer patients. Given the results of Cox proportional hazard regression analysis, two members of RDGN were involved in the present predictive model and patients with high model index had poorer outcomes.ConclusionThis study showed that aberrant RDGN expression was an unfavorable factor for breast cancer. This RDGN-based comprehensively framework was meaningful for predicting the prognosis of breast cancer patients.
Highlights
In the United States, breast cancer is the most commonly diagnosed cancer and second leading cause of cancerrelated death in women [1, 2]
KEGG pathways and GO‐terms enrichments Based on dataset GSE25066, we separately analyzed the difference of gene profiles for high and low expression of DACH1, EYA2 and SIX1
Decreased DACH1 predicting poor prognosis of breast cancer Based on the expression profiles from The Cancer Genome Atlas (TCGA) database, we compared the DACH1 level between normal breast tissues and breast cancer samples
Summary
In the United States, breast cancer is the most commonly diagnosed cancer and second leading cause of cancerrelated death in women [1, 2]. According to the presence or absence of molecular biomarkers, breast cancer could be categorized into three major subtypes: Luminal (hormone receptor positive and Her-2 negative), Her-2-enriched (Her-2 amplified), Basal-like (hormone receptor negative and Her-2 negative) [3]. The molecular typing of breast cancer is a huge breakthrough in cancer theranostics which helps to predict the prognosis of. Apart from molecular typing, tumor DNA sequencing is an important reference for treatment decision. Breast cancer is the most diagnosed malignancy in females in the United States. A comprehensive predictive model of RDGN might be helpful to herald the prognosis of breast cancer patients
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
